Fen-Phen Risks Won’t Color U.S. FDA Diet Pill Review
Fen-Phen Risks Won’t Color U.S. FDA Diet Pill Review
U.S. regulators won’t re-examine safety data from fen-phen, the recalled diet drug tied to heart damage, as they review a new generation of weight-loss pills led by Vivus Inc.’s Qnexa that use some of the same ingredients.
Read more on BusinessWeek
Similar Blogs
- Qnexa Review | Slimming Pills Review
- Weight Loss Pills: You Must Know The Truth | quitsmokinghelp4u.com
- Time to Rethink Fannie and Freddie – BusinessWeek | Mortgage Chat Online
- Vivus, Arena Obesity Drugs Won’t Be Judged by Fen-Phen Risk, U.S. FDA Says
- Vivus Inc (VVUS): Qnexa Analysis Part V » GekkoWire
- Vivus Inc. (VVUS): Next Week’s FDA Briefing Documents » GekkoWire
- Fen-Phen Risks Won’t Color U.S. FDA Diet Pill Review
- Ayurvedic, Unani, Siddha herbal products need safety and efficacy data from human clinical testing in India | DWS Pill Scribe
- BB Bulletin.com » Blog Archive » Businessweek's Brady Discusses RIM Blackberry Smartphone: VideoGoogle Alerts – blackberry
- The Unknown Effects Of Weight Loss Diet Pill | 78messages.com
- » Vivus Inc (VVUS) $9.86 +3.68% WhatsTrading.com: Objective Real Time Market Intelligence
- Liking the new Bloomberg Businessweek « Talking Biz News
Related Products:
